ANGiographic Evaluation of Left Main Coronary Artery INtErvention (ANGELINE)
Primary Purpose
Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis
Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Angiography and Clinical Follow up
Clinical Follow up
Sponsored by
About this trial
This is an interventional treatment trial for Coronary Occlusion focused on measuring Angiography
Eligibility Criteria
Inclusion Criteria:
- Age: 18- 85 years at the date of the PCI.
- With PCI for presenting de novo lesions in the Left Main Artery by implanting a cobalt-chrome stent with everolimus-eluting fluoropolymer.
- Informed consent signed.
Exclusion Criteria:
- Refusal to participate in the study.
- Patients with left main disease who have been admitted with STEMI and have undergone primary angioplasty in a culprit lesion different than the left main. The left main lesion has been treated as a stage procedure and discharged with left ventricular ejection fraction < 35 %.
- Previous coronary surgery.
- Creatinine clearance <40 ml / min.
- Contraindication for double antiaggregation after PCI.
- Patients life expectancy <36 months.
- Included in other studies or clinical trials.
- Pregnant or lactating women.
Sites / Locations
- Hospital Universitari Germans Trias I PujolRecruiting
- Hospital Universitario de CrucesRecruiting
- Hospital Universitario DonostiaRecruiting
- Hospital Universitario Regional de MalagaRecruiting
- Hospital Galdakao-UsansoloRecruiting
- Hospital General Universitario de AlbaceteRecruiting
- Hospital General Universitario de AlicanteRecruiting
- Hospital Universitario San Juan de AlicanteRecruiting
- Hospital Del MarRecruiting
- Hospital Universitari Vall D'HebronRecruiting
- Hospital Universitari BellvitgeRecruiting
- Hospital Universitario de Ciudad RealRecruiting
- Hospital Universitario de A CoruñaRecruiting
- Hospital Universitario Reina SofiaRecruiting
- Hospital Universitario de CabueñesRecruiting
- Hospital Universitario Virgen de Las NievesRecruiting
- Hospital General Juan Ramón JiménezRecruiting
- Hospital Universitario de LeónRecruiting
- Hospital Universitario Lucus AgustiRecruiting
- Hospital Universitario La PrincesaRecruiting
- Hospital Universitario Ramon Y CajalRecruiting
- Hospital Universitario 12 de OctubreRecruiting
- Hospital Universitario La PazRecruiting
- Hospital Universitario Virgen ArrixacaRecruiting
- Hospital Universitario Marques de ValdecillaRecruiting
- Hospital Clínico Universitario de Santiago de CompostelaRecruiting
- Hospital Clinico Universitario de ValenciaRecruiting
- Hospital Clinico Universitario de ValladolidRecruiting
- Hospital Clinico Universitario Lozano BlesaRecruiting
- Hospital Universitario Miguel ServetRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Angiography and Clinical Follow up
Clinical Follow up
Arm Description
After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
After PCI. The patient is randomized to a Clinical Follow to 36 months
Outcomes
Primary Outcome Measures
Composite endpoint: defined as : death, myocardial infarction, and stroke.
Composite endpoint: defined as : death, myocardial infarction, and stroke.
Secondary Outcome Measures
All Death
Occurrence of Death
Cardiac Death
Occurrence of Cardiac Death
Myocardial Infarction
Occurrence of Myocardial Infarction
Stroke
Occurrence of Stroke
Stent thrombosis (ARC definite/probable)
Occurrence of thrombosis (ARC definite/probable)
Major bleeding event (BARC type 2-5)
Occurrence of Major bleeding event (BARC type 2-5)
Target Vessel revascularization.
Occurrence of Target Vessel revascularization.
Revascularization by CABG ( Coronary Artery Bypass Grafting) or PCI (Percutaneous Coronary Intervention)
Occurrence of New revascularization by CABG or PCI
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04604197
Brief Title
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
Acronym
ANGELINE
Official Title
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 16, 2021 (Actual)
Primary Completion Date
December 1, 2025 (Anticipated)
Study Completion Date
December 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fundación EPIC
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.
Detailed Description
Percutaneous coronary intervention (PCI) with drug-eluting stents in left main (LM) disease has demonstrated similar results than surgical revascularization in patients with SYNTAX score < 33, being the main drawback of PCI a higher rate of new revascularization. A small study found a reduction in the composite end-point of cardiac death, myocardial infarction and urgent revascularization with a routine angiographic follow-up. The investigators have designed a prospective, randomized, controlled, two-arm multicenter study in patients aged 18-85 with LM disease and SYNTAX score <33 and in cases ≥ 33 based on the Heart Team decision to assess the benefit of a routine angiographic follow-up 6 months after LM stenting. After the index procedure and before hospital discharge the patient will be randomized to routine invasive angiographic follow-up at 6 months plus clinical follow-up at 6 months, 1, 2 and 3 years vs. the control arm, which would be followed clinically at 6 months, 1, 2 and 3 years. Based on our calculations, an adequately powered trial would require 1009 patients per arm but due to the uncertainty of the results and the current economical restrictions we have designed a pilot study in 400 patients to find out the convenience of an adequately powered trial. All the lesions should be treated with an everolimus eluting stent with permanent fluoropolymer. It will be desirable to achieve complete revascularization and it will be highly recommended to perform the procedures guided with an intravascular image technique (OCT or IVUS (IntraVascular UltraSound) according to operator´s criteria). The main outcome will be death, myocardial infarction and cerebrovascular accident at 3 years. The initial percutaneous technique and the decision about the convenience and way of revascularization in case of restenosis in the follow-up will be left at the operator´s discretion, according in the most adequate way to the current guidelines. Nonetheless, the investigators are strongly encouraged to rely on intravascular techniques, based on either imaging or physiology. In those cases with in-stent hyperplasia with doubts about possible restenosis, FFR and RFR (Resting full-cycle ratio) will be performed, with low threshold to achieve a high rate of ruling out the restenosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
Keywords
Angiography
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Angiography and Clinical Follow up
Arm Type
Experimental
Arm Description
After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
Arm Title
Clinical Follow up
Arm Type
Active Comparator
Arm Description
After PCI. The patient is randomized to a Clinical Follow to 36 months
Intervention Type
Other
Intervention Name(s)
Angiography and Clinical Follow up
Intervention Description
Angiography and Clinical Follow up
Intervention Type
Other
Intervention Name(s)
Clinical Follow up
Intervention Description
Clinical Follow up
Primary Outcome Measure Information:
Title
Composite endpoint: defined as : death, myocardial infarction, and stroke.
Description
Composite endpoint: defined as : death, myocardial infarction, and stroke.
Time Frame
36 months
Secondary Outcome Measure Information:
Title
All Death
Description
Occurrence of Death
Time Frame
36 months
Title
Cardiac Death
Description
Occurrence of Cardiac Death
Time Frame
36 months
Title
Myocardial Infarction
Description
Occurrence of Myocardial Infarction
Time Frame
36 months
Title
Stroke
Description
Occurrence of Stroke
Time Frame
36 months
Title
Stent thrombosis (ARC definite/probable)
Description
Occurrence of thrombosis (ARC definite/probable)
Time Frame
36 months
Title
Major bleeding event (BARC type 2-5)
Description
Occurrence of Major bleeding event (BARC type 2-5)
Time Frame
36 months
Title
Target Vessel revascularization.
Description
Occurrence of Target Vessel revascularization.
Time Frame
36 months
Title
Revascularization by CABG ( Coronary Artery Bypass Grafting) or PCI (Percutaneous Coronary Intervention)
Description
Occurrence of New revascularization by CABG or PCI
Time Frame
36 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 18- 85 years at the date of the PCI.
With PCI for presenting de novo lesions in the Left Main Artery by implanting a cobalt-chrome stent with everolimus-eluting fluoropolymer.
Informed consent signed.
Exclusion Criteria:
Refusal to participate in the study.
Patients with left main disease who have been admitted with STEMI and have undergone primary angioplasty in a culprit lesion different than the left main. The left main lesion has been treated as a stage procedure and discharged with left ventricular ejection fraction < 35 %.
Previous coronary surgery.
Creatinine clearance <40 ml / min.
Contraindication for double antiaggregation after PCI.
Patients life expectancy <36 months.
Included in other studies or clinical trials.
Pregnant or lactating women.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Iñigo Lozano, MD, PhD
Phone
+34987876135
Email
ilozano@fundacionepic.org
First Name & Middle Initial & Last Name or Official Title & Degree
Fundacion Epic
Phone
+34987876135
Email
iepic@fundacionepic.org
Facility Information:
Facility Name
Hospital Universitari Germans Trias I Pujol
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario de Cruces
City
Barakaldo
State/Province
Bizkaia
ZIP/Postal Code
48903
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Donostia
City
Donostia
State/Province
Gipuzkoa
ZIP/Postal Code
20014
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Regional de Malaga
City
Málaga
State/Province
Malaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Galdakao-Usansolo
City
Galdakao
State/Province
Vizcaya
ZIP/Postal Code
48960
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario de Albacete
City
Albacete
ZIP/Postal Code
02006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Universitario de Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario San Juan de Alicante
City
Alicante
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Vall D'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitari Bellvitge
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario de Ciudad Real
City
Ciudad Real
ZIP/Postal Code
13005
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario de A Coruña
City
Coruña
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Reina Sofia
City
Córdoba
ZIP/Postal Code
14004
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario de Cabueñes
City
Gijón
ZIP/Postal Code
33394
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen de Las Nieves
City
Granada
ZIP/Postal Code
18014
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital General Juan Ramón Jiménez
City
Huelva
ZIP/Postal Code
21005
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario de León
City
León
ZIP/Postal Code
24071
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Lucus Agusti
City
Lugo
ZIP/Postal Code
27003
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario La Princesa
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Ramon Y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Virgen Arrixaca
City
Murcia
ZIP/Postal Code
30120
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Marques de Valdecilla
City
Santander
ZIP/Postal Code
39008
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clínico Universitario de Santiago de Compostela
City
Santiago De Compostela
ZIP/Postal Code
15706
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario de Valladolid
City
Valladolid
ZIP/Postal Code
47003
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clinico Universitario Lozano Blesa
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Universitario Miguel Servet
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
12. IPD Sharing Statement
Citations:
PubMed Identifier
27585503
Citation
Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farooq V, Tateishi H, Tenekecioglu E, Zeng Y, Suwannasom P, Collet C, Albuquerque FN, Onuma Y, Park SJ, Serruys PW. Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. J Am Coll Cardiol. 2016 Sep 6;68(10):999-1009. doi: 10.1016/j.jacc.2016.06.024.
Results Reference
background
PubMed Identifier
28040444
Citation
Puri R, de la Torre Hernandez JM, Auffret V. Routine Surveillance Coronary Angiography Post-PCI: Should We ReACT and Change Our Routine? JACC Cardiovasc Interv. 2017 Jan 23;10(2):118-120. doi: 10.1016/j.jcin.2016.11.020. Epub 2016 Dec 28. No abstract available.
Results Reference
background
PubMed Identifier
30155864
Citation
Aurigemma C, Burzotta F, Porto I, Niccoli G, Leone AM, Crea F, Trani C. Clinical impact of routine angiographic follow-up after percutaneous coronary interventions on unprotected left main. Cardiol J. 2018;25(5):582-588. doi: 10.5603/CJ.a2018.0092. Epub 2018 Aug 29.
Results Reference
background
PubMed Identifier
27797291
Citation
Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogats G, Mansour S, Noiseux N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Page P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016 Dec 8;375(23):2223-2235. doi: 10.1056/NEJMoa1610227. Epub 2016 Oct 31. Erratum In: N Engl J Med. 2019 Oct 31;381(18):1789.
Results Reference
background
PubMed Identifier
27810312
Citation
Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, Trovik T, Eskola M, Romppanen H, Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, Linder RB, Pentikainen M, Hervold A, Banning A, Zaman A, Cotton J, Eriksen E, Margus S, Sorensen HT, Nielsen PH, Niemela M, Kervinen K, Lassen JF, Maeng M, Oldroyd K, Berg G, Walsh SJ, Hanratty CG, Kumsars I, Stradins P, Steigen TK, Frobert O, Graham AN, Endresen PC, Corbascio M, Kajander O, Trivedi U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016 Dec 3;388(10061):2743-2752. doi: 10.1016/S0140-6736(16)32052-9. Epub 2016 Oct 31. Erratum In: Lancet. 2016 Dec 3;388(10061):2742.
Results Reference
background
PubMed Identifier
31562798
Citation
Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM 3rd, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogats G, Mansour S, Noiseux N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Page P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Genereux P, Crowley A, Dressler O, Serruys PW; EXCEL Trial Investigators. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28. Erratum In: N Engl J Med. 2020 Mar 12;382(11):1078.
Results Reference
background
Learn more about this trial
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
We'll reach out to this number within 24 hrs